Cipla to tap foreign cos for large-scale vax play
Moving beyond a wide portfolio of Covid drugs and diagnostic kits, the Mumbai-based company — with revenues of nearly Rs 20,000 crore — now plans to partner foreign companies for large-scale fill-and-finish services for coronavirus vaccines.
via Economictimes
Post a Comment